An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2025, is one of 15 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 28th registered.
365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in China
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2014; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 200 is below the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 59 across the 17 interventional studies, 200 across the 15 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06146660Bristol-Myers SquibbA Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | 2026-11-30 |
| NCT07557498Bristol-Myers SquibbMavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US | 2026-12-14 |
| NCT07541833Bristol-Myers SquibbEffectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) | 2026-12-31 |
| NCT06551129Bristol-Myers SquibbReal-world Patient Reported Outcomes Among Patients Treated With Camzyos | 2026-12-31 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
The study population will consist of adults diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiate mavacamten treatment at medical institutions in Japan
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with obstructive hypertrophic cardiomyopathy receiving mavacamten treatment
Drug: Mavacamten
According to the product label
Incidence of adverse events (AEs) and/or serious AEs (SAEs)
Time frame: Up to 52 weeks
Actions taken after adverse events (AEs) and/or serious AEs (SAEs)
Time frame: Up to 52 weeks
Outcome of adverse events (AEs) and/or serious AEs (SAEs)
Time frame: Up to 52 weeks
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Nov 2029, 54 months after the start.
Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 54 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →